Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

Leveraging Bicycle Conjugates as Radio-Imaging & Theragnostic Agents to Inform Early Clinical Therapeutic Development

By | 8 June 2026

Exploring human data generated from Gallium-68 imaging studies with Bicycle molecules
Laying out the latest preclinical data of Bicycle Drug Conjugates
Delving into Gallium-68 PET imaging with Bicycle Molecules to guide clinical development of therapeutic conjugates